top of page
Green tea is a rich source of catechins, a group of flavonoids including epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC). These natural compounds have garnered significant interest due to their potential pharmacological activities. Our research is dedicated to modifying the structure of these natural catechins to enhance their therapeutic efficacy. We are particularly focused on developing novel treatments for idiopathic pulmonary fibrosis (IPF), Alzheimer's disease (AD), and nonalcoholic steatohepatitis (NASH). By optimizing the properties of catechins, we aim to create more potent and selective agents that can effectively target the pathological mechanisms underlying these diseases, offering new hope for patients affected by these challenging conditions.

Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by the scarring (fibrosis) of lung tissue, leading to a decline in lung function over time. The exact cause of IPF remains unknown, making it a challenging condition to treat. Recent research has focused on the potential use of epigallocatechin gallate (EGCG), a polyphenol found in green tea, for the treatment of IPF. EGCG has shown promise in preclinical studies for its anti-inflammatory and anti-fibrotic properties. Currently, EGCG is being evaluated in a Phase 1 clinical trial for its safety and efficacy in IPF patients. Our team is building on this research by designing new analogs of EGCG to enhance its therapeutic activity. By modifying the chemical structure of EGCG, we aim to improve its bioavailability, selectivity, and potency, making it a more effective treatment option for IPF.

Nonalcoholic steatohepatitis (NASH)

Liver fibrosis, a critical stage in the progression of nonalcoholic steatohepatitis (NASH), is a growing concern in the realm of liver diseases. NASH, an advanced form of nonalcoholic fatty liver disease (NAFLD), can lead to severe complications such as cirrhosis, liver failure, or liver cancer. In recent years, epigallocatechin gallate (EGCG), a potent antioxidant found in green tea, has gained attention for its potential therapeutic effects on liver fibrosis and NASH. EGCG has shown anti-inflammatory and anti-fibrotic properties in preclinical studies, offering a promising avenue for treatment. However, the bioavailability and efficacy of EGCG can be limited, prompting researchers to explore the design of new analogs. By modifying the chemical structure of EGCG, scientists aim to enhance its activity, selectivity, and pharmacokinetic properties, making it a more effective and targeted therapy for liver fibrosis and NASH.

Alzheimer's Disease (AD)

Alzheimer's disease is a devastating neurodegenerative disorder that presents a significant challenge in the quest for effective treatments. It is characterized by progressive memory loss and cognitive decline, severely impacting the lives of those affected. Recent research has identified epigallocatechin gallate (EGCG), a bioactive compound found in green tea, as a potential therapeutic agent for Alzheimer's disease. Studies in animal models have shown positive data, suggesting that EGCG may possess neuroprotective properties that could help slow the progression of the disease. Building on this promising foundation, our team is focused on designing new analogs of EGCG to enhance its therapeutic efficacy. Specifically, we are targeting the DYRK1A enzyme, which is believed to play a crucial role in the pathogenesis of Alzheimer's disease. By developing more potent and selective compounds that can effectively inhibit the DYRK1A enzyme, we aim to create improved treatment options that can address the underlying mechanisms of Alzheimer's disease and offer hope for those affected by this debilitating condition.
bottom of page